Reaction
Lymphadenectomy reporting signals
As of the last recalculation, Lymphadenectomy appears in 966 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE (PRR 32.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Conjugated Estrogens And Medroxyprogesterone Acetate | 34 | 32.1 | 32.2 |
| Cefuroxime | 14 | 26.8 | 26.8 |
| Dextrose | 14 | 23.2 | 23.3 |
| Dextrose Monohydrate | 14 | 22.9 | 22.9 |
| Piperacillin And Tazobactam | 12 | 20.5 | 20.5 |
| Gentamicin | 12 | 20.0 | 20.0 |
| Gentamicin Sulfate | 14 | 19.4 | 19.4 |
| Dornase Alfa | 15 | 16.7 | 16.7 |
| Medroxyprogesterone Acetate | 36 | 16.1 | 16.1 |
| Pembrolizumab | 70 | 15.4 | 15.4 |
| Conjugated Estrogens | 38 | 14.6 | 14.6 |
| Estrogens, Conjugated | 38 | 14.3 | 14.3 |
| Piperacillin Sodium,Tazobactam Sodium | 17 | 14.0 | 14.0 |
| Sulfasalazine | 48 | 13.9 | 13.9 |
| Pyrazinamide | 5 | 11.5 | 11.5 |
| Ado-Trastuzumab Emtansine | 4 | 10.3 | 10.3 |
| Encorafenib | 4 | 8.7 | 8.7 |
| Cetuximab | 11 | 7.6 | 7.6 |
| Pegfilgrastim | 26 | 5.8 | 5.8 |
| Ixekizumab | 7 | 4.1 | 4.1 |
| Relugolix | 4 | 3.7 | 3.7 |